The WHO ACTION-III Trial: antenatal corticosteroids for improving outcomes in preterm newborns
A multi-country, multi-centre, three-arm, parallel group, double-blind, placebo controlled, randomized trial of two doses of antenatal corticosteroids for women with a high probability of birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes.
The aim of this trial is to assess the benefits and possible harms of two regimens of antenatal corticosteroids, dexamethasone phosphate 4x6mg IM q12h and betamethasone phosphate 4x2mg IM q12h, compared to placebo, when given to pregnant women in the late preterm period (gestation age of 34+0 to 36+5 weeks) when they are at risk of preterm birth.
WHO Department of Sexual and Reproductive Health and Research UNDP/UNFPA/UNICEF/
WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP)
WHO Department of Maternal, Newborn, Child and Adolescent Health and Ageing
Johns Hopkins Bloomberg School of Public Health International Center for Maternal and Newborn Health
Bangabandhu Sheikh Mujib Medical University Dhaka, Bangladesh
KLE University’s Jawaharlal Nehru Medical College Belgaum, Karnataka, India
Kenyatta National Hospital Nairobi, Kenya
University of Nairobi Nairobi, Kenya
University of Ibadan Nigeria
Obafemi Awolowo University Ile-Ife, Osun State, Nigeria
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present. We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
Oops!
It looks like something may have gone wrong, and some of the resources required to load the page may not have loaded correctly.
